PuSH - Publikationsserver des Helmholtz Zentrums München: Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Demel, U.M.* ; Boger, M.* ; Yousefian, S.* ; Grunert, C.* ; Zhang, L.* ; Hotz, P.W.* ; Gottschlich, A.* ; Köse, H.* ; Isaakidis, K.* ; Vonficht, D.* ; Grünschläger, F.* ; Rohleder, E.* ; Wagner, K.* ; Dönig, J.* ; Igl, V.* ; Brzezicha, B.* ; Baumgartner, F.* ; Habringer, S.* ; Löber, J.* ; Chapuy, B.* ; Weidinger, C.* ; Kobold, S. ; Busse, A.B.* ; Müller, S.* ; Wirth, M.* ; Schick, M.* ; Keller, U.*

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.

J. Clin. Invest. 132:e152383 (2022)

Postprint

Forschungsdaten

DOI

PMC

	Open Access Hybrid

Abstract
Metriken
Zusatzinfos

Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells to evade CD8+ T cell-mediated immunosurveillance by suppressing the MHC class I (MHC-I) antigen-processing and presentation machinery (APM). Loss of the MHC-I APM is a frequent cause of resistance to cancer immunotherapies, and the pharmacological inhibition of SUMOylation (SUMOi) resulted in reduced activity of the transcriptional repressor scaffold attachment factor B (SAFB) and induction of the MHC-I APM. Consequently, SUMOi enhanced the presentation of antigens and the susceptibility of tumor cells to CD8+ T cell-mediated killing. Importantly, SUMOi also triggered the activation of CD8+ T cells and thereby drove a feed-forward loop amplifying the specific antitumor immune response. In summary, we showed that activated SUMOylation allowed tumor cells to evade antitumor immunosurveillance, and we have expanded the understanding of SUMOi as a rational therapeutic strategy for enhancing the efficacy of cancer immunotherapies.

Impact Factor

Scopus SNIP

Altmetric

19.456

0.000